In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the ... in the format of pre-filled disposable pen and cartridges (Penfill and FlexPen). The company recently ...

Consumers looking to start the popular weight loss drug Wegovy but lacking insurance coverage will soon have a new option. Novo Nordisk ... and requires a manual syringe. Dr. Tara Narula, ABC ...

These vials are administered through traditional syringes. According to documents cited in the earlier report, Novo Nordisk had informed ... such as Ozempic and Wegovy, which it plans to introduce ...

an NFC-enabled add-on for prefilled syringes called Injay, and Datapen, a smart pen injector compatible with standard cartridges and adaptable to dual chamber cartridges. “Novo Nordisk has ...

cartridges, and prefilled syringes. The company serves over 100 pharmaceutical customers and operates three manufacturing facilities across India with a capacity of over 3 billion units annually. This ...

This decision is part of the company's global strategy to prioritize newer, patented therapies such as Ozempic and Wegovy ... pens and cartridges (Penfill and FlexPen). According to a recent media ...

That’s what some are wondering after Novo Nordisk ... Wegovy) to wealthier nations, its decision to withdraw human insulin pens may push people with diabetes in resource-limited settings, who rely on ...

Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They will prioritize newer, patented therapies like Ozempic and ...

The Diabetes Injection Pens Market is expected to witness a growth rate of ~7% by 2028. The key factors driving the market are the rising prevalence of diabetes, the growing preference for pens over ...

Consumers looking to start the popular weight loss drug Wegovy but lacking insurance coverage will soon have a new option. Novo Nordisk, the maker of Wegovy ... comes in vials and requires a manual ...

Medical Dialogues had earlier reported that Novo Nordisk is phasing out several pen-fill and cartridge-based insulin formulations — including its popular brand Mixtard, as part of its global portfolio ...